Summary of Key Points Core Viewpoint - The stock of Ailis experienced a slight increase of 0.02% on September 9, closing at 115.35 yuan, with significant block trades occurring during the day [1]. Trading Activity - A total of 5 block trades were executed, with a combined trading volume of 426,400 shares and a total transaction value of 44.7592 million yuan [1]. - The first four trades all occurred at a price of 104.97 yuan per share, with a consistent discount of -9.00% from the market price [1][2]. - The fifth trade also matched the price of 104.97 yuan, maintaining the same discount rate [2]. Recent Trading Trends - Over the past three months, Ailis has recorded a total of 60 block trades, amounting to a cumulative transaction value of 777 million yuan [2]. - In the last five trading days, the stock has seen a marginal increase of 0.05%, while the main capital has experienced a net outflow of 76.6955 million yuan [2].

9月9日，艾力斯大宗交易成交42.64万股，成交额4475.92万元，占当日总成交额的5.34%，成交价104.97 元，较市场收盘价115.35元折价9%。 | 交易日期 | 证券間除 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 图书能用品 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-09 | 艾力斯 | 688578 | 104.97 | 1678.47 | 15.99 | 华金证券股份有限 公司上海纪程路证 | 中信证券股份有限 公司上海分公司 | 播 | | | | | | | | 登富不留 | | | | 2025-09-09 | 艾力斯 | 688578 | 104.97 11:40 | 1621.79 | 15.45 | 机构专用 | 中信证券股份有限 公司上海分公司 | Ka | | 2025-09-09 | 艾力斯 | 688578 | V-274383 104.97 | 497.56 | 4.74 | 华金证券股份有限 公司上海纪程路证 ...

Core Viewpoint - The stock of Ailis has shown significant growth in 2023, with a year-to-date increase of 97.82%, indicating strong market performance and investor interest [1][2]. Company Overview - Ailis Pharmaceutical Technology Co., Ltd. was established on March 22, 2004, and went public on December 2, 2020. The company is primarily engaged in the research, production, and sales of innovative drugs [1]. - The main revenue source for Ailis is drug sales, accounting for 99.93% of total revenue, with promotional services contributing 0.06% [1]. Financial Performance - For the first half of 2025, Ailis reported a revenue of 2.374 billion yuan, representing a year-on-year growth of 50.57%. The net profit attributable to shareholders was 1.051 billion yuan, reflecting a 60.22% increase compared to the previous year [2]. - Since its A-share listing, Ailis has distributed a total of 653 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period. The average number of circulating shares per shareholder was 34,578, down by 3.48% [2]. - Notable institutional shareholders include the Huaxia SSE STAR 50 ETF, which holds 12.42 million shares, and the Hong Kong Central Clearing Limited, which holds 10.38 million shares [3].

机构评级来看，近5日共有4家机构给予该股评级，预计目标价最高的是国泰海通证券，9月3日国泰海通 证券发布的研报预计公司目标价为128.60元。（数据宝） 9月8日艾力斯大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 6.90 | 724.16 | 104.95 | -9.00 | 摩根大通证券（中国）有限公司 | 中信证券股份有限 | | | | | | 上海银城中路证券营业部 | 公司上海分公司 | | 3.10 | 325.35 | 104.95 | -9.00 | 摩根大通证券（中国）有限公司 | 中信证券股份有限 | | | | | | 上海银城中路证券营业部 | 公司上海分公司 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 艾力斯9月8日大宗交易平台共发生2笔成交，合计成交量10.00万股，成交金额1049.51万元 ...

（文章来源：证券日报） 证券日报网讯 9月8日晚间，艾力斯发布公告称，公司计划于2025年9月16日（星期二）15：00-17：00 参与由上海证券交易所主办的2025年半年度科创板创新药行业集体业绩说明会。 ...

第2笔成交价格为104.95元，成交3.10万股，成交金额325.35万元，溢价率为-9.00%，买方营业部为摩根 大通证券（中国）有限公司上海银城中路证券营业部，卖方营业部为中信证券股份有限公司上海分公 司。 进一步统计，近3个月内该股累计发生55笔大宗交易，合计成交金额为7.33亿元。该股近5个交易日累计 下跌1.41%，主力资金合计净流出1.52亿元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月8日，艾力斯收跌1.64%，收盘价为115.33元，发生2笔大宗交易，合计成交量10万股，成交金额 1049.51万元。 第1笔成交价格为104.95元，成交6.90万股，成交金额724.16万元，溢价率为-9.00%，买方营业部为摩根 大通证券（中国）有限公司上海银城中路证券营业部，卖方营业部为中信证券股份有限公司上海分公 司。 ...

Core Insights - On September 8, a block trade of 100,000 shares of Ailis was executed, amounting to 10.4951 million yuan, which represented 1.41% of the total trading volume for that day. The transaction price was 104.95 yuan, reflecting a 9% discount compared to the market closing price of 115.33 yuan [1]. Summary by Categories Trading Activity - A block trade of 100,000 shares of Ailis was completed on September 8, 2025, with a total transaction value of 10.4951 million yuan [1]. - The transaction price was set at 104.95 yuan per share, which is a 9% discount from the market closing price of 115.33 yuan [1]. Market Impact - The block trade accounted for 1.41% of the total trading volume on that day, indicating a significant transaction relative to overall market activity [1].

证券代码：688578 证券简称：艾力斯 公告编号：2025-022 上海艾力斯医药科技股份有限公司 关于参加 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 公司已于 2025 年 8 月 27 日在上海证券交易所网站（www.sse.com.cn）披露 公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年 度经营成果、财务状况及发展理念，公司计划于 2025 年 9 月 16 日（星期二） 15:00-17:00 参与由上海证券交易所主办的 2025 年半年度科创板创新药行业集体 业绩说明会，就投资者关心的问题进行交流。 一、业绩说明会类型 本次业绩说明会以网络文字互动形式召开，公司将针对 2025 年半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、业绩说明会召开的时间 ...

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

Group 1 - The core point of the news is that on September 5, a total of 10 block trades occurred for Ailis, with a total trading volume of 583,600 shares and a transaction amount of 62.27 million yuan, at a price of 106.70 yuan, which is a 9% discount compared to the closing price of the day [1][2] - Institutional specialized seats appeared in 5 of the block trades, with a total transaction amount of 29.49 million yuan, indicating a net purchase of 29.49 million yuan by these institutions [1][2] - Over the past three months, Ailis has recorded a total of 53 block trades, with a cumulative transaction amount of 722 million yuan [1] Group 2 - The latest margin financing balance for Ailis is 915 million yuan, which has increased by 66.71 million yuan over the past five days, representing a growth of 7.87% [2] - In the past five days, five institutions have rated Ailis, with the highest target price set at 128.60 yuan by Guotai Junan Securities on September 3 [2]